Kedrion and Biotest Reach Major Distribution Agreement
Kedrion Biopharma Inc. and Biotest AG have recently signed a long-term exclusive distribution agreement for Yimmugo®, marking a significant step in their collaboration. This agreement is built on the preliminary framework established earlier, and it lays the groundwork for the full commercialization of this essential immunoglobulin therapy in the United States.
Details of the Agreement
The finalized contract stipulates that Biotest must supply minimum quantities of Yimmugo®, while Kedrion is set to purchase these quantities over an initial seven-year period. This partnership is vital as they prepare for the product's launch in the US, projected for 2025.
Understanding Yimmugo® and Its Importance
Yimmugo® is an immunoglobulin G preparation derived from human blood plasma, specifically formulated to treat Primary Immunodeficiencies (PID). These conditions affect around 500,000 individuals in the US alone, highlighting a pressing need for effective treatments.
Production and Quality Assurance
Production of Yimmugo® will commence immediately, following the approval of the Biologic License Application (BLA). The state-of-the-art manufacturing facility in Dreieich, Germany, is FDA-certified and aims to maintain high product quality standards while ensuring sustainable resource usage during the production process.
Market Potential and Future Plans
With expectations of approximately 9% annual growth in the US immunoglobulin market over the next few years, Kedrion's distribution of Yimmugo® is strategically positioned to meet increasing demand. This collaboration not only aims to facilitate market access but also to reach more patients suffering from Primary Immunodeficiency disorders.
Commitment to Patient Care
Bob Rossilli, Chief Commercial Officer at Kedrion, expressed the company’s dedication to understanding patient needs, emphasizing their excitement about introducing Yimmugo® to the US market. As awareness of Primary Immunodeficiency conditions grows, Kedrion sees a fantastic opportunity to make a significant difference in the lives of those affected.
About Kedrion Biopharma
Kedrion Biopharma is a prominent biopharmaceutical company engaged in collecting and processing blood plasma to create vital therapies. Their focus lies in treating rare and debilitating conditions, including various coagulation disorders and Primary Immunodeficiencies. The company boasts a workforce of 5,100 employees globally, with a presence in over 100 countries and a diverse portfolio of 37 products.
Commitment to Sustainability
Kedrion is recognized for its sustainability efforts within the biopharmaceutical sector, employing innovative technologies to assure the quality and effectiveness of its plasma-derived products while minimizing environmental impact. Their commitment extends to expanding global access to therapies that significantly improve patient outcomes.
Frequently Asked Questions
What is Yimmugo® used for?
Yimmugo® is used to treat Primary Immunodeficiencies, providing essential immunoglobulin therapy for patients with compromised immune systems.
How long is the distribution agreement between Kedrion and Biotest?
The distribution agreement spans an initial period of seven years, with options for renewal based on market performance.
What are the growth prospects for the immunoglobulin market?
The US immunoglobulin market is projected to grow at an annual rate of approximately 9% over the next several years, indicating strong demand for products like Yimmugo®.
Where is Yimmugo® produced?
Yimmugo® is produced at Biotest's FDA-certified facility located in Dreieich, Germany, utilizing advanced manufacturing processes.
Who can benefit from Yimmugo® therapy?
Patients aged 2 years and older suffering from Primary Immunodeficiencies can benefit from Yimmugo® therapy, which is designed to help manage their condition effectively.
